{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:12Z","timestamp":1785131952604,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04204-3","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:31:41Z","timestamp":1774762301000},"page":"283-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase-specific impact of hypogammaglobulinemia on bacterial infections after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"124","author":[{"given":"Hidekatsu","family":"Yae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0388-3836","authenticated-orcid":false,"given":"Mitsutaka","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"7","key":"4204_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3466","volume":"13","author":"A Durandy","year":"2013","unstructured":"Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol. 2013;13(7):519\u201333.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4204_CR2","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciu646","volume":"59","author":"C Aguilar","year":"2014","unstructured":"Aguilar C, Malphettes M, Donadieu J, Chandesris O, Coignard-Biehler H, Catherinot E, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59(10):1462\u201370.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4204_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s10875-022-01317-2","volume":"42","author":"MN Syed","year":"2022","unstructured":"Syed MN, Kutac C, Miller JM, Marsh R, Sullivan KE, Cunningham-Rundles C, et al. Risk factors of Pneumonia in primary antibody deficiency patients receiving immunoglobulin therapy: data from the US Immunodeficiency Network (USIDNET). J Clin Immunol. 2022;42(7):1545\u201352.","journal-title":"J Clin Immunol"},{"key":"4204_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033","volume":"10","author":"SY Patel","year":"2019","unstructured":"Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.","journal-title":"Front Immunol"},{"issue":"10","key":"4204_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","volume":"57","author":"K Wudhikarn","year":"2022","unstructured":"Wudhikarn K, Perales MA. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transpl. 2022;57(10):1477\u201388.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"4204_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.64","volume":"4","author":"G Zugmaier","year":"2014","unstructured":"Zugmaier G, Topp MS, Alekar S, Viardot A, Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):244.","journal-title":"Blood Cancer J"},{"issue":"5","key":"4204_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjh.12067","volume":"159","author":"D Oscier","year":"2012","unstructured":"Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541\u201364.","journal-title":"Br J Haematol"},{"key":"4204_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","volume":"191","author":"A Vacca","year":"2018","unstructured":"Vacca A, Melaccio A, Sportelli A, Solimando AG, Dammacco F, Ria R. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018;191:110\u20135.","journal-title":"Clin Immunol"},{"key":"4204_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100596","volume":"38","author":"JA Hill","year":"2019","unstructured":"Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev. 2019;38:100596.","journal-title":"Blood Rev"},{"key":"4204_CR10","doi-asserted-by":"publisher","first-page":"1544025","DOI":"10.3389\/fmed.2025.1544025","volume":"12","author":"Z Guo","year":"2025","unstructured":"Guo Z, Zhu J, Wang J, Wang L, Tang F, Huang H, et al. Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases. Front Med (Lausanne). 2025;12:1544025.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"4204_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70091","volume":"6","author":"K Mihara","year":"2025","unstructured":"Mihara K, Kawase T, Miyama T, Iwasaki K, Shoji A, Matsumaru M. The real world impact of immunoglobulin replacement therapy on severe bacterial infection for patients with hypogammaglobulinemia secondary to hematologic malignancies: a Japanese claims database study. EJHaem. 2025;6(4):e70091.","journal-title":"EJHaem"},{"issue":"1","key":"4204_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21\u201330.","journal-title":"Clin Immunol"},{"issue":"6","key":"4204_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2014.28","volume":"49","author":"Y Arai","year":"2014","unstructured":"Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, et al. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transpl. 2014;49(6):859\u201361.","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"4204_CR14","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s00277-021-04649-y","volume":"100","author":"E Karakulska-Prystupiuk","year":"2021","unstructured":"Karakulska-Prystupiuk E, Dwilewicz-Trojaczek J, Drozd-Soko\u0142owska J, Kmin E, Chlebus M, Szczypi\u0144ska K, et al. Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis. Ann Hematol. 2021;100(12):3007\u201316.","journal-title":"Ann Hematol"},{"issue":"10","key":"4204_CR15","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/trf.14656","volume":"58","author":"H Ahn","year":"2018","unstructured":"Ahn H, Tay J, Shea B, Hutton B, Shorr R, Knoll GA, et al. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transfusion. 2018;58(10):2437\u201352.","journal-title":"Transfusion"},{"issue":"5","key":"4204_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1200\/JCO.2008.16.8450","volume":"27","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2009;27(5):770\u201381.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4204_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41409-022-01680-z","volume":"57","author":"A Ohmoto","year":"2022","unstructured":"Ohmoto A, Fuji S, Shultes KC, Savani BN, Einsele H. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transpl. 2022;57(6):874\u201380.","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"4204_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transpl. 2009;15(10):1143\u2013238.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"4204_CR19","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"A Freifeld","year":"2011","unstructured":"Freifeld A, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56-93.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4204_CR20","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.bbmt.2015.05.019","volume":"21","author":"T Hahn","year":"2015","unstructured":"Hahn T, Sucheston-Campbell LE, Preus L, Zhu X, Hansen JA, Martin PJ, et al. Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21(9):1679\u201386.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"15","key":"4204_CR21","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2024015477","volume":"9","author":"E O'Donnell","year":"2025","unstructured":"O\u2019Donnell E, Gift T, Yousif Z, Khandelwal N, Desai R, Huynh L, et al. Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma. Blood Adv. 2025;9(15):3780\u20139.","journal-title":"Blood Adv"},{"issue":"12","key":"4204_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"4204_CR23","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"key":"4204_CR24","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825\u20138."},{"issue":"3","key":"4204_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389-401.e1.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"4204_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"4204_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","volume":"41","author":"AC Norlin","year":"2008","unstructured":"Norlin AC, Sairafi D, Mattsson J, Ljungman P, Ringd\u00e9n O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transpl. 2008;41(3):267\u201373.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"4204_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.blre.2017.09.003","volume":"32","author":"M Ueda","year":"2018","unstructured":"Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev. 2018;32(2):106\u201315.","journal-title":"Blood Rev"},{"issue":"1","key":"4204_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-139-1-200307010-00007","volume":"139","author":"C Cordonnier","year":"2003","unstructured":"Cordonnier C, Chevret S, Legrand M, Rafi H, Dh\u00e9din N, Lehmann B, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med. 2003;139(1):8\u201318.","journal-title":"Ann Intern Med"},{"issue":"2","key":"4204_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ajh.22229","volume":"87","author":"JE Howell","year":"2012","unstructured":"Howell JE, Gulbis AM, Champlin RE, Qazilbash MH. Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol. 2012;87(2):172\u20134.","journal-title":"Am J Hematol"},{"issue":"4","key":"4204_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/ejh.13686","volume":"107","author":"V Lacombe","year":"2021","unstructured":"Lacombe V, Nunes Gomes C, Robin JB, Th\u00e9pot S, Fran\u00e7ois S, Cottin L, et al. Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations. Eur J Haematol. 2021;107(4):489\u201396.","journal-title":"Eur J Haematol"},{"key":"4204_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.987231","volume":"13","author":"S Pedraza-S\u00e1nchez","year":"2022","unstructured":"Pedraza-S\u00e1nchez S, Cruz-Gonz\u00e1lez A, Palmeros-Rojas O, G\u00e1lvez-Romero JL, Bellanti JA, Torres M. Polyvalent human immunoglobulin for infectious diseases: potential to circumvent antimicrobial resistance. Front Immunol. 2022;13:987231.","journal-title":"Front Immunol"},{"issue":"5","key":"4204_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14712598.8.5.583","volume":"8","author":"J Storek","year":"2008","unstructured":"Storek J. Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. Expert Opin Biol Ther. 2008;8(5):583\u201397.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"4204_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bjh.19203","volume":"204","author":"M Suga","year":"2024","unstructured":"Suga M, Fuji S, Tada Y, Tsutsumi K, Kida S, Shibata K, et al. A single-institution pre-post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients. Br J Haematol. 2024;204(1):260\u20137.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04204-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:36Z","timestamp":1785128676000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4204"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04204-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H. has received research funding from Takeda Pharmaceuticals and the Japan Blood Products Organization, as well as speaker\u2019s honoraria from Takeda Pharmaceuticals. H.N. has received research funding and speaker\u2019s honoraria from Takeda Pharmaceuticals. H.O. has received research funding from Takeda Pharmaceuticals. M. Nishimoto has received speaker\u2019s honoraria from CSL Behring. The other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}